Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Goodwill & Intangibles (2016 - 2025)

Historic Goodwill & Intangibles for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to $32.4 billion.

  • Gsk's Goodwill & Intangibles rose 1480.05% to $32.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $32.4 billion, marking a year-over-year increase of 1480.05%. This contributed to the annual value of $28.8 billion for FY2024, which is 714.18% up from last year.
  • Gsk's Goodwill & Intangibles amounted to $32.4 billion in Q3 2025, which was up 1480.05% from $29.5 billion recorded in Q2 2025.
  • In the past 5 years, Gsk's Goodwill & Intangibles ranged from a high of $56.3 billion in Q3 2021 and a low of $21.8 billion during Q2 2022
  • For the 5-year period, Gsk's Goodwill & Intangibles averaged around $34.0 billion, with its median value being $28.7 billion (2024).
  • As far as peak fluctuations go, Gsk's Goodwill & Intangibles tumbled by 6085.77% in 2022, and later skyrocketed by 2795.36% in 2023.
  • Over the past 5 years, Gsk's Goodwill & Intangibles (Quarter) stood at $54.8 billion in 2021, then tumbled by 54.25% to $25.1 billion in 2022, then grew by 6.88% to $26.8 billion in 2023, then increased by 7.81% to $28.9 billion in 2024, then grew by 12.04% to $32.4 billion in 2025.
  • Its last three reported values are $32.4 billion in Q3 2025, $29.5 billion for Q2 2025, and $29.2 billion during Q1 2025.